Companion diagnostics for the targeted therapy of gastric cancer.
Gastric cancer is the fourth most common type of cancer and represents a major cause of cancer-related deaths worldwide. With recent biomedical advances in our understanding of the molecular characteristics of gastric cancer, many genetic alterations have been identified as potential targets for its treatment. Multiple novel agents are currently under development as the demand for active agents that improve the survival of gastric cancer patients constantly increases. Based on lessons from previous trials of targeted agents, it is now widely accepted that the establishment of an optimal diagnostic test to select molecularly defined patients is of equal importance to the development of active agents against targetable genetic alterations. Herein, we highlight the current status and future perspectives of companion diagnostics in the treatment of gastric cancer.
Changhoon Yoo, Departments of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, South Korea.
Changhoon
C
Yoo
Changhoon Yoo, Departments of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 138-736, South Korea.
Young Soo
YS
Park
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D025202:Molecular Diagnostic Techniques; D058990:Molecular Targeted Therapy; D018579:Patient Selection; D057285:Precision Medicine; D011237:Predictive Value of Tests; D011379:Prognosis; D015398:Signal Transduction / Q000187:drug effects; D013274:Stomach Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
Companion diagnostics; Fibroblast growth factor receptor; Gastric cancer; Hepatocyte growth factor receptor; Human epidermal growth factor receptor 2